DDInter814 DDInter1435
Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody [FDA Label]. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death. Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Gemtuzumab ozogamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Gemtuzumab ozogamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Gemtuzumab ozogamicin {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Gemtuzumab ozogamicin {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Gemtuzumab ozogamicin may lead to a major life threatening interaction when taken with Lomitapide
Gemtuzumab ozogamicin may lead to a major life threatening interaction when taken with Etanercept